MDACC Study No:2011-0287 ( NCT No: NCT01440179)
Title:Phase II two stage dose finding run-in study of SAR3419, an anti-CD19 antibody-maytansine conjugate, administered as a single agent by intravenous infusion in patients with relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Principal Investigator:Hagop Kantarjian
Treatment Agent:SAR3419
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if SAR3419 can help to
control ALL. The safety of the study drug will also be studied.

SAR3419 is a substance that can locate and bind to CD19, a molecule that is
found on most ALL cells. This may cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:SAR3419
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Sanofi-Aventis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults